GRAND RAPIDS, Mich., Sept. 12, 2025 (GLOBE NEWSWIRE) — Steelcase Inc. (NYSE: SCS) will webcast a discussion of its second quarter fiscal year 2026 financial results on Thursday, September 25, 2025 at 8:30 a.m. ET. A link to the webcast will be available at http://ir.steelcase.com and a replay of the webcast will be available shortly after the call concludes. The news release detailing the financial results will be issued the previous day, September 24, 2025, after the market closes.  About Steelcase Inc.  Steelcase (NYSE: SCS) is a global design and thought leader in the world of work. Our purpose is to help the world work better. Along with more than 30 creative and technology partner brands, we research, design and manufacture furnishings and solutions for many of the places where work happens — including offices, homes, and...

Kinetic donated $7,500 as well as Goods, Services to Broken Arrow Neighbors, Soldier’s Wish Free community appreciation event featured local vendors, food, and entertainmentBROKEN ARROW, Okla., Sept. 12, 2025 (GLOBE NEWSWIRE) — Kinetic, a leading provider of residential and business fiber internet services, gathered employees from across the area here for a week-long “Kinetic Commitment to Community” event. The week began with Kinetic employees volunteering with two local nonprofit organizations within Broken Arrow for days of service, including:Donating a much-needed ping pong table to the Broken Arrow Senior Center for local seniors to enjoy, complete with all equipment necessary for a great afternoon. Gathering at Broken Arrow Neighbors for a community service outreach event to provide local families in need with meals,...

Regulated informationIssy-les-Moulineaux, September 12, 2025 Monthly disclosure on share capital and voting rights (amended: cancel and replace the publication of September 3, 2025) Pursuant to Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers Registered name of the issuer: SODEXO255, quai de la Bataille de Stalingrad – 92130 ISSY-LES-MOULINEAUXDate Total number of shares Actual voting rights * Theoretical voting rights **August 31, 2025147,454,887216,928,941218,451,268* Actual voting rights: all of the Company shares have the same voting rights, except for treasury shares which do not have voting rights and registered shares held for more than four years, which have double voting rights. ** Theoretical voting rights: the number of...

ISELIN, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) — Middlesex Water Company (NASDAQ: MSEX) has announced that its Chair, President and Chief Executive Officer, Nadine Leslie, and Senior Vice President, Chief Financial Officer and Treasurer, Mohammed G. (Rally) Zerhouni, are scheduled to participate in the 5th Annual Virtual Water Utilities Conference hosted by Janney Montgomery Scott on Wednesday, September 17, 2025 at 8:00am ET. Mrs. Leslie and Mr. Zerhouni will discuss the Company business strategy. The conference is a virtual event moderated by Michael Gaugler, Janney’s Senior Analyst and Managing Director, Utility & Infrastructure. The live webcast of the fireside chat will be available at https://wsw.com/webcast/jms14/msex/1695155 and will also be posted on Middlesex Water’s website www.middlesexwater.com under Investors...

AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) — via IBN — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“OTLC” or the “Company”),  a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today announces a summary of its major accomplishments over the past two years. These milestones underscore meaningful clinical progress and regulatory validation across the Company’s lead drug candidates. Oncotelic’s pipeline includes multiple late-stage programs targeting oncology and rare diseases, with several drug candidates achieving significant clinical milestones Two-Year Clinical Progress SnapshotOT-101 (TGF-β inhibitor): Phase 3 for pancreatic cancer, with additional applications in ARDS/COVID-19 OXi4503 (vascular disrupting agent): Phase 2 in...

   Evolution of Société BIC’s Board of Directors composition Clichy, France – September 12, 2025 – During its meeting held today, and upon recommendation of the Nominations, Governance and CSR Committee, the Board of Directors has coopted three new Directors, which cooptation will be submitted for ratification at the next Shareholders’ Meeting of May 2026:Rob Versloot, Société BIC’s new CEO as of September 15, 2025, replaces Gonzalve Bich as Director. As announced in December 2024, Gonzalve Bich will continue to serve as Senior Advisor to the Group. Albert Baladi, an experienced and highly respected leader in the consumer goods industry, replaces Jake Schwartz, who has decided to step down from his role as Independent Director. Albert Baladi will be a member of the Audit Committee and of the Nominations, Governance and CSR Committee. Geoffroy...

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to admit Abivax to the CAC Mid 60 and SBF 120 indices. This decision will take effect on Friday, September 19, 2025, after market close. The CAC Mid 60 and SBF 120 are key indices on the Euronext Paris exchange, representing mid-sized listed companies...

Solid revenue growth in the first half of 2025 of +5.6% at constant exchange rates and scopeAdjusted recurring operating income² of 18.3% as a ratio to revenue, in line with our expectationsDown compared to 2024 due to phasing and non-recurring effects2025 targets confirmedRevenue growth expected between 4% and 6% at constant rates and scope Adjusted recurring operating income¹ expected around 16%CONSOLIDATED FIGURES AS OF JUNE 30in € million HY25 HY24 Variance 2025/2024       Revenues 738.3 702.9 5.0%Change at constant exchange rates1     7.8%Change at constant exchange rates and scope1     5.6%       Current operating profit, before amortization of assets arising from acquisitions2 135.0 150.4 -10.2%as a % of revenue 18.3% 21.4%  as a % of...